483 Amphastar Nanjing Pharmaceuticals Oct 2019

483 Amphastar Nanjing Pharmaceuticals Oct 2019

Angela Glenn FDA$119.00 - Available Now

FDA investigators audited the Amphastar Nanjing Pharmaceuticals - Nanjing, China facility and issued inspectional observations (via FDA 483) on 11 Oct 2019.

Product details

  • Category: Human Drugs
  • Inspection end: 11 Oct 2019
  • Location: Nanjing, China
  • FEI: 3009805706
Add To Cart